PubMed:24283717
Annnotations
Inflammaging
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 0-127 | Sentence | denotes | Deletion of thioredoxin-interacting protein preserves retinal neuronal function by preventing inflammation and vascular injury. |
| T2 | 128-151 | Sentence | denotes | BACKGROUND AND PURPOSE: |
| T3 | 152-255 | Sentence | denotes | Retinal neurodegeneration is an early and critical event in several diseases associated with blindness. |
| T4 | 256-313 | Sentence | denotes | Clinically, therapies that target neurodegeneration fail. |
| T5 | 314-467 | Sentence | denotes | We aimed to elucidate the multiple roles by which thioredoxin-interacting protein (TXNIP) contributes to initial and sustained retinal neurodegeneration. |
| T6 | 468-490 | Sentence | denotes | EXPERIMENTAL APPROACH: |
| T7 | 491-601 | Sentence | denotes | Neurotoxicity was induced by intravitreal injection of NMDA into wild-type (WT) and TXNIP-knockout (TKO) mice. |
| T8 | 602-716 | Sentence | denotes | The expression of apoptotic and inflammatory markers was assessed by immunohistochemistry, elisa and Western blot. |
| T9 | 717-849 | Sentence | denotes | Microvascular degeneration was assessed by periodic acid-Schiff and haematoxylin staining and retinal function by electroretinogram. |
| T10 | 850-1078 | Sentence | denotes | KEY RESULTS: NMDA induced early (1 day) and significant retinal PARP activation, a threefold increase in TUNEL-positive nuclei and 40% neuronal loss in ganglion cell layer (GCL); and vascular permeability in WT but not TKO mice. |
| T11 | 1079-1199 | Sentence | denotes | NMDA induced glial activation, expression of TNF-α and IL-1β that co-localized with Müller cells in WT but not TKO mice. |
| T12 | 1200-1379 | Sentence | denotes | In parallel, NMDA triggered the expression of NOD-like receptor protein (NLRP3), activation of caspase-1, and release of IL-1β and TNF-α in primary WT but not TKO Müller cultures. |
| T13 | 1380-1563 | Sentence | denotes | After 14 days, NMDA induced 1.9-fold microvascular degeneration, 60% neuronal loss in GCL and increased TUNEL-labelled cells in the GCL and inner nuclear layer in WT but not TKO mice. |
| T14 | 1564-1670 | Sentence | denotes | Electroretinogram analysis showed more significant reductions in b-wave amplitudes in WT than in TKO mice. |
| T15 | 1671-1699 | Sentence | denotes | CONCLUSION AND IMPLICATIONS: |
| T16 | 1700-1889 | Sentence | denotes | Targeting TXNIP expression prevented early retinal ganglion cell death, glial activation, retinal inflammation and secondary neuro/microvascular degeneration and preserved retinal function. |
| T17 | 1890-1973 | Sentence | denotes | TXNIP is a promising new therapeutic target for retinal neurodegenerative diseases. |
| T1 | 0-127 | Sentence | denotes | Deletion of thioredoxin-interacting protein preserves retinal neuronal function by preventing inflammation and vascular injury. |
| T2 | 128-151 | Sentence | denotes | BACKGROUND AND PURPOSE: |
| T3 | 152-255 | Sentence | denotes | Retinal neurodegeneration is an early and critical event in several diseases associated with blindness. |
| T4 | 256-313 | Sentence | denotes | Clinically, therapies that target neurodegeneration fail. |
| T5 | 314-467 | Sentence | denotes | We aimed to elucidate the multiple roles by which thioredoxin-interacting protein (TXNIP) contributes to initial and sustained retinal neurodegeneration. |
| T6 | 468-490 | Sentence | denotes | EXPERIMENTAL APPROACH: |
| T7 | 491-601 | Sentence | denotes | Neurotoxicity was induced by intravitreal injection of NMDA into wild-type (WT) and TXNIP-knockout (TKO) mice. |
| T8 | 602-716 | Sentence | denotes | The expression of apoptotic and inflammatory markers was assessed by immunohistochemistry, elisa and Western blot. |
| T9 | 717-849 | Sentence | denotes | Microvascular degeneration was assessed by periodic acid-Schiff and haematoxylin staining and retinal function by electroretinogram. |
| T10 | 850-1078 | Sentence | denotes | KEY RESULTS: NMDA induced early (1 day) and significant retinal PARP activation, a threefold increase in TUNEL-positive nuclei and 40% neuronal loss in ganglion cell layer (GCL); and vascular permeability in WT but not TKO mice. |
| T11 | 1079-1199 | Sentence | denotes | NMDA induced glial activation, expression of TNF-α and IL-1β that co-localized with Müller cells in WT but not TKO mice. |
| T12 | 1200-1379 | Sentence | denotes | In parallel, NMDA triggered the expression of NOD-like receptor protein (NLRP3), activation of caspase-1, and release of IL-1β and TNF-α in primary WT but not TKO Müller cultures. |
| T13 | 1380-1563 | Sentence | denotes | After 14 days, NMDA induced 1.9-fold microvascular degeneration, 60% neuronal loss in GCL and increased TUNEL-labelled cells in the GCL and inner nuclear layer in WT but not TKO mice. |
| T14 | 1564-1670 | Sentence | denotes | Electroretinogram analysis showed more significant reductions in b-wave amplitudes in WT than in TKO mice. |
| T15 | 1671-1699 | Sentence | denotes | CONCLUSION AND IMPLICATIONS: |
| T16 | 1700-1889 | Sentence | denotes | Targeting TXNIP expression prevented early retinal ganglion cell death, glial activation, retinal inflammation and secondary neuro/microvascular degeneration and preserved retinal function. |
| T17 | 1890-1973 | Sentence | denotes | TXNIP is a promising new therapeutic target for retinal neurodegenerative diseases. |
sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| TextSentencer_T1 | 0-127 | Sentence | denotes | Deletion of thioredoxin-interacting protein preserves retinal neuronal function by preventing inflammation and vascular injury. |
| TextSentencer_T2 | 128-151 | Sentence | denotes | BACKGROUND AND PURPOSE: |
| TextSentencer_T3 | 152-255 | Sentence | denotes | Retinal neurodegeneration is an early and critical event in several diseases associated with blindness. |
| TextSentencer_T4 | 256-313 | Sentence | denotes | Clinically, therapies that target neurodegeneration fail. |
| TextSentencer_T5 | 314-467 | Sentence | denotes | We aimed to elucidate the multiple roles by which thioredoxin-interacting protein (TXNIP) contributes to initial and sustained retinal neurodegeneration. |
| TextSentencer_T6 | 468-490 | Sentence | denotes | EXPERIMENTAL APPROACH: |
| TextSentencer_T7 | 491-601 | Sentence | denotes | Neurotoxicity was induced by intravitreal injection of NMDA into wild-type (WT) and TXNIP-knockout (TKO) mice. |
| TextSentencer_T8 | 602-716 | Sentence | denotes | The expression of apoptotic and inflammatory markers was assessed by immunohistochemistry, elisa and Western blot. |
| TextSentencer_T9 | 717-849 | Sentence | denotes | Microvascular degeneration was assessed by periodic acid-Schiff and haematoxylin staining and retinal function by electroretinogram. |
| TextSentencer_T10 | 850-1078 | Sentence | denotes | KEY RESULTS: NMDA induced early (1 day) and significant retinal PARP activation, a threefold increase in TUNEL-positive nuclei and 40% neuronal loss in ganglion cell layer (GCL); and vascular permeability in WT but not TKO mice. |
| TextSentencer_T11 | 1079-1199 | Sentence | denotes | NMDA induced glial activation, expression of TNF-α and IL-1β that co-localized with Müller cells in WT but not TKO mice. |
| TextSentencer_T12 | 1200-1379 | Sentence | denotes | In parallel, NMDA triggered the expression of NOD-like receptor protein (NLRP3), activation of caspase-1, and release of IL-1β and TNF-α in primary WT but not TKO Müller cultures. |
| TextSentencer_T13 | 1380-1563 | Sentence | denotes | After 14 days, NMDA induced 1.9-fold microvascular degeneration, 60% neuronal loss in GCL and increased TUNEL-labelled cells in the GCL and inner nuclear layer in WT but not TKO mice. |
| TextSentencer_T14 | 1564-1670 | Sentence | denotes | Electroretinogram analysis showed more significant reductions in b-wave amplitudes in WT than in TKO mice. |
| TextSentencer_T15 | 1671-1699 | Sentence | denotes | CONCLUSION AND IMPLICATIONS: |
| TextSentencer_T16 | 1700-1889 | Sentence | denotes | Targeting TXNIP expression prevented early retinal ganglion cell death, glial activation, retinal inflammation and secondary neuro/microvascular degeneration and preserved retinal function. |
| TextSentencer_T17 | 1890-1973 | Sentence | denotes | TXNIP is a promising new therapeutic target for retinal neurodegenerative diseases. |
| T1 | 0-127 | Sentence | denotes | Deletion of thioredoxin-interacting protein preserves retinal neuronal function by preventing inflammation and vascular injury. |
| T2 | 128-151 | Sentence | denotes | BACKGROUND AND PURPOSE: |
| T3 | 152-255 | Sentence | denotes | Retinal neurodegeneration is an early and critical event in several diseases associated with blindness. |
| T4 | 256-313 | Sentence | denotes | Clinically, therapies that target neurodegeneration fail. |
| T5 | 314-467 | Sentence | denotes | We aimed to elucidate the multiple roles by which thioredoxin-interacting protein (TXNIP) contributes to initial and sustained retinal neurodegeneration. |
| T6 | 468-490 | Sentence | denotes | EXPERIMENTAL APPROACH: |
| T7 | 491-601 | Sentence | denotes | Neurotoxicity was induced by intravitreal injection of NMDA into wild-type (WT) and TXNIP-knockout (TKO) mice. |
| T8 | 602-716 | Sentence | denotes | The expression of apoptotic and inflammatory markers was assessed by immunohistochemistry, elisa and Western blot. |
| T9 | 717-849 | Sentence | denotes | Microvascular degeneration was assessed by periodic acid-Schiff and haematoxylin staining and retinal function by electroretinogram. |
| T10 | 850-1078 | Sentence | denotes | KEY RESULTS: NMDA induced early (1 day) and significant retinal PARP activation, a threefold increase in TUNEL-positive nuclei and 40% neuronal loss in ganglion cell layer (GCL); and vascular permeability in WT but not TKO mice. |
| T11 | 1079-1199 | Sentence | denotes | NMDA induced glial activation, expression of TNF-α and IL-1β that co-localized with Müller cells in WT but not TKO mice. |
| T12 | 1200-1379 | Sentence | denotes | In parallel, NMDA triggered the expression of NOD-like receptor protein (NLRP3), activation of caspase-1, and release of IL-1β and TNF-α in primary WT but not TKO Müller cultures. |
| T13 | 1380-1563 | Sentence | denotes | After 14 days, NMDA induced 1.9-fold microvascular degeneration, 60% neuronal loss in GCL and increased TUNEL-labelled cells in the GCL and inner nuclear layer in WT but not TKO mice. |
| T14 | 1564-1670 | Sentence | denotes | Electroretinogram analysis showed more significant reductions in b-wave amplitudes in WT than in TKO mice. |
| T15 | 1671-1699 | Sentence | denotes | CONCLUSION AND IMPLICATIONS: |
| T16 | 1700-1889 | Sentence | denotes | Targeting TXNIP expression prevented early retinal ganglion cell death, glial activation, retinal inflammation and secondary neuro/microvascular degeneration and preserved retinal function. |
| T17 | 1890-1973 | Sentence | denotes | TXNIP is a promising new therapeutic target for retinal neurodegenerative diseases. |
DisGeNET
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T0 | 914-918 | gene:142 | denotes | PARP |
| T1 | 1002-1010 | disease:C0085648 | denotes | ganglion |
| T2 | 914-918 | gene:142 | denotes | PARP |
| T3 | 1002-1010 | disease:C1258666 | denotes | ganglion |
| T4 | 914-918 | gene:1302 | denotes | PARP |
| T5 | 1002-1010 | disease:C0085648 | denotes | ganglion |
| T6 | 914-918 | gene:1302 | denotes | PARP |
| T7 | 1002-1010 | disease:C1258666 | denotes | ganglion |
| R1 | T0 | T1 | associated_with | PARP,ganglion |
| R2 | T2 | T3 | associated_with | PARP,ganglion |
| R3 | T4 | T5 | associated_with | PARP,ganglion |
| R4 | T6 | T7 | associated_with | PARP,ganglion |
PubmedHPO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 160-177 | HP_0002180 | denotes | neurodegeneration |
| T2 | 245-254 | HP_0000618 | denotes | blindness |
| T3 | 290-307 | HP_0002180 | denotes | neurodegeneration |
| T4 | 449-466 | HP_0002180 | denotes | neurodegeneration |
Allie
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| SS1_24283717_4_0 | 364-395 | expanded | denotes | thioredoxin-interacting protein |
| SS2_24283717_4_0 | 397-402 | abbr | denotes | TXNIP |
| SS1_24283717_6_0 | 556-565 | expanded | denotes | wild-type |
| SS2_24283717_6_0 | 567-569 | abbr | denotes | WT |
| SS1_24283717_6_1 | 575-589 | expanded | denotes | TXNIP-knockout |
| SS2_24283717_6_1 | 591-594 | abbr | denotes | TKO |
| SS1_24283717_10_0 | 1002-1021 | expanded | denotes | ganglion cell layer |
| SS2_24283717_10_0 | 1023-1026 | abbr | denotes | GCL |
| AE1_24283717_4_0 | SS1_24283717_4_0 | SS2_24283717_4_0 | abbreviatedTo | thioredoxin-interacting protein,TXNIP |
| AE1_24283717_6_0 | SS1_24283717_6_0 | SS2_24283717_6_0 | abbreviatedTo | wild-type,WT |
| AE1_24283717_6_1 | SS1_24283717_6_1 | SS2_24283717_6_1 | abbreviatedTo | TXNIP-knockout,TKO |
| AE1_24283717_10_0 | SS1_24283717_10_0 | SS2_24283717_10_0 | abbreviatedTo | ganglion cell layer,GCL |
DisGeNET5_gene_disease
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| 24283717-12#10#15#gene10628 | 1710-1715 | gene10628 | denotes | TXNIP |
| 24283717-12#51#59#diseaseC0085648 | 1751-1759 | diseaseC0085648 | denotes | ganglion |
| 24283717-12#51#59#diseaseC1258666 | 1751-1759 | diseaseC1258666 | denotes | ganglion |
| 24283717-13#0#5#gene10628 | 1890-1895 | gene10628 | denotes | TXNIP |
| 24283717-13#56#82#diseaseC0524851 | 1946-1972 | diseaseC0524851 | denotes | neurodegenerative diseases |
| 24283717-7#51#55#gene1302 | 914-918 | gene1302 | denotes | PARP |
| 24283717-7#51#55#gene142 | 914-918 | gene142 | denotes | PARP |
| 24283717-7#139#147#diseaseC0085648 | 1002-1010 | diseaseC0085648 | denotes | ganglion |
| 24283717-7#139#147#diseaseC1258666 | 1002-1010 | diseaseC1258666 | denotes | ganglion |
| 24283717-7#139#147#diseaseC0085648 | 1002-1010 | diseaseC0085648 | denotes | ganglion |
| 24283717-7#139#147#diseaseC1258666 | 1002-1010 | diseaseC1258666 | denotes | ganglion |
| 10#15#gene1062851#59#diseaseC0085648 | 24283717-12#10#15#gene10628 | 24283717-12#51#59#diseaseC0085648 | associated_with | TXNIP,ganglion |
| 10#15#gene1062851#59#diseaseC1258666 | 24283717-12#10#15#gene10628 | 24283717-12#51#59#diseaseC1258666 | associated_with | TXNIP,ganglion |
| 0#5#gene1062856#82#diseaseC0524851 | 24283717-13#0#5#gene10628 | 24283717-13#56#82#diseaseC0524851 | associated_with | TXNIP,neurodegenerative diseases |
| 51#55#gene1302139#147#diseaseC0085648 | 24283717-7#51#55#gene1302 | 24283717-7#139#147#diseaseC0085648 | associated_with | PARP,ganglion |
| 51#55#gene1302139#147#diseaseC1258666 | 24283717-7#51#55#gene1302 | 24283717-7#139#147#diseaseC1258666 | associated_with | PARP,ganglion |
| 51#55#gene1302139#147#diseaseC0085648 | 24283717-7#51#55#gene1302 | 24283717-7#139#147#diseaseC0085648 | associated_with | PARP,ganglion |
| 51#55#gene1302139#147#diseaseC1258666 | 24283717-7#51#55#gene1302 | 24283717-7#139#147#diseaseC1258666 | associated_with | PARP,ganglion |
| 51#55#gene142139#147#diseaseC0085648 | 24283717-7#51#55#gene142 | 24283717-7#139#147#diseaseC0085648 | associated_with | PARP,ganglion |
| 51#55#gene142139#147#diseaseC1258666 | 24283717-7#51#55#gene142 | 24283717-7#139#147#diseaseC1258666 | associated_with | PARP,ganglion |
| 51#55#gene142139#147#diseaseC0085648 | 24283717-7#51#55#gene142 | 24283717-7#139#147#diseaseC0085648 | associated_with | PARP,ganglion |
| 51#55#gene142139#147#diseaseC1258666 | 24283717-7#51#55#gene142 | 24283717-7#139#147#diseaseC1258666 | associated_with | PARP,ganglion |
DisGeNet-2017-sample
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T189 | 1710-1715 | gene:10628 | denotes | TXNIP |
| T190 | 1751-1759 | disease:C0085648 | denotes | ganglion |
| R1 | T189 | T190 | associated_with | TXNIP,ganglion |
| R2 | T189 | T190 | associated_with | TXNIP,ganglion |
UBERON-AE
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| PD-UBERON-AE-B_T1 | 1002-1010 | http://purl.obolibrary.org/obo/UBERON_0000045 | denotes | ganglion |
| PD-UBERON-AE-B_T2 | 1751-1759 | http://purl.obolibrary.org/obo/UBERON_0000045 | denotes | ganglion |
| PD-UBERON-AE-B_T3 | 1011-1021 | http://purl.obolibrary.org/obo/UBERON_0000119 | denotes | cell layer |
performance-test
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| PD-UBERON-AE-B_T1 | 62-70 | http://purl.obolibrary.org/obo/UBERON_2000602 | denotes | neuronal |
| PD-UBERON-AE-B_T2 | 985-993 | http://purl.obolibrary.org/obo/UBERON_2000602 | denotes | neuronal |
| PD-UBERON-AE-B_T3 | 1449-1457 | http://purl.obolibrary.org/obo/UBERON_2000602 | denotes | neuronal |
| PD-UBERON-AE-B_T4 | 1002-1010 | http://purl.obolibrary.org/obo/UBERON_0000045 | denotes | ganglion |
| PD-UBERON-AE-B_T5 | 1751-1759 | http://purl.obolibrary.org/obo/UBERON_0000045 | denotes | ganglion |
| PD-UBERON-AE-B_T6 | 1011-1021 | http://purl.obolibrary.org/obo/UBERON_0000119 | denotes | cell layer |